Duttaroy A, Yoburn B C
Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, Queens, New York 11439, USA.
Anesthesiology. 1995 May;82(5):1226-36. doi: 10.1097/00000542-199505000-00018.
The intrinsic efficacy of opioid analgesics has been suggested to play a role in the development of tolerance to these agents. However, the effect of differences in dosing protocol on tolerance to opioid analgesics of high or low efficacy has not been addressed. Therefore, the effect of opioid intrinsic efficacy on tolerance in mice was determined in protocols of continuous and intermittent administration of equieffective doses of opioid agonists.
Initial antinociceptive median effective doses (ED50s) for five opioid agonists that vary in intrinsic efficacy were estimated in untreated mice. Groups of mice received continuous infusions of morphine, fentanyl, or etorphine for 72 h or 7 days from osmotic minipumps implanted subcutaneously. The infusion doses were calculated as multiples of the initial antinociceptive ED50. An inert placebo was implanted subcutaneously in controls. At the end of treatment, the pumps and placebos were removed, and 4-24 h later, mice were tested in dose-response studies (tail flick) using the same drug that had been chronically administered. In another study using intermittent dosing, mice received subcutaneous injections every 24 h for 3 days of saline or morphine, etorphine, fentanyl, oxycodone, or meperidine, or received subcutaneous injections every 24 h for 7 days of saline or morphine, etorphine, or fentanyl. Daily doses were calculated as multiples of the initial antinociceptive ED50. Twenty-four hours after the last injection, mice were tested in dose-response studies.
High-intrinsic-efficacy compounds (e.g., etorphine and fentanyl) produced less tolerance than a lower-intrinsic-efficacy drug (morphine) in 72-h and 7-day infusion studies. Tolerance for all compounds after intermittent treatment with equieffective doses was similar, and intrinsic efficacy had no effect on the magnitude of tolerance after intermittent dosing.
These results indicate that the intrinsic efficacy of opioid analgesics is inversely related to the degree of tolerance after continuous infusion, but that intrinsic efficacy does not significantly affect tolerance after once-daily intermittent administration of these agents. These findings may be of clinical utility in understanding the development of tolerance to the antinociceptive effects of opioids.
阿片类镇痛药的内在效能被认为在对这些药物的耐受性发展中起作用。然而,给药方案的差异对高效或低效阿片类镇痛药耐受性的影响尚未得到探讨。因此,在等效剂量阿片类激动剂持续和间歇给药方案中,确定了阿片类药物内在效能对小鼠耐受性的影响。
在未处理的小鼠中估计了五种内在效能不同的阿片类激动剂的初始抗伤害感受半数有效剂量(ED50)。小鼠组通过皮下植入的渗透微型泵接受吗啡、芬太尼或埃托啡的持续输注72小时或7天。输注剂量计算为初始抗伤害感受ED50的倍数。对照组皮下植入惰性安慰剂。治疗结束时,取出泵和安慰剂,4至24小时后,使用长期给药的相同药物对小鼠进行剂量反应研究(甩尾试验)。在另一项使用间歇给药的研究中,小鼠每24小时皮下注射一次生理盐水或吗啡、埃托啡、芬太尼、羟考酮或哌替啶,共3天,或每24小时皮下注射一次生理盐水或吗啡、埃托啡或芬太尼,共7天。每日剂量计算为初始抗伤害感受ED50的倍数。最后一次注射24小时后,对小鼠进行剂量反应研究。
在72小时和7天的输注研究中,高内在效能化合物(如埃托啡和芬太尼)产生的耐受性低于低内在效能药物(吗啡)。等效剂量间歇治疗后,所有化合物的耐受性相似,内在效能对间歇给药后的耐受程度没有影响。
这些结果表明,阿片类镇痛药的内在效能与持续输注后的耐受程度呈负相关,但内在效能对这些药物每日一次间歇给药后的耐受性没有显著影响。这些发现可能有助于理解阿片类药物抗伤害感受作用耐受性的发展。